Overview
On 22 October 2007, orphan designation (EU/3/07/496) was granted by the European Commission to Only for Children Pharmaceuticals, France, for mercaptopurine (oral liquid) for the treatment of acute lymphoblastic leukaemia.
The sponsorship was transferred to Orbona Pharma Ltd, United Kingdom, in October 2013.
For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.
Key facts
Active substance |
Mercaptopurine
|
Intended use |
Treatment of acute lymphoblastic leukaemia
|
Orphan designation status |
Positive
|
EU designation number |
EU/3/07/496
|
Date of designation |
22/10/2007
|
Sponsor |
Orbona Pharma Ltd
Old Chambers 93-94 West Street Farnham Surrey GU97EB United Kingdom Tel. +44 (0)1252 21 63 27 Fax +44 (0)1252 72 08 24 E-mail: sglass@orbona.co.uk |
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: